APPLICANT PROGRAM
IngenBio is built on the principles of making quality products and providing reliable intelligence and research.
Our diversified product range continues to grow by following trends, improving our standard products, and listening to the customer.
We strongly support the National Interagency Biodefense Campus (NIBC) as a result of Executive Branch and Congressional direction that addresses leveraging and expanding key competencies to achieve productive and efficient interagency cooperation in support of Homeland Security Biodefense.
Our unique service has established our place in this industry. This allows us to make a distinctive and substantial impact in the biodefense community.
High-quality people make a strong, dynamic company. Ingen Bio understands this truth. You will be joining our well-established group in a great location, with plenty of practice growth potential. This outstanding opportunity marks the beginning of your career, and we want to make sure the time you spend with us is filled with meaningful work in your field of expertise. You'll be treated and respected as a valuable contributor and given your own responsibilities and accountabilities. Your intern experience with us will include work evaluations that will provide you with valuable professional feedback to gauge your strengths and identify areas of improvement.
We will offer new opportunities in the following divisions:
Biological Defense Research
40.CFR.10.B6111
This research program focuses on investigating aspects of bacterial pathogenesis, immunology, and human model intervention utilizing potential biological warfare threat agents. The scope of research also includes preclinical research and development studies on potential candidates for dissemination, vaccines and control groups focusing on infectious agents of military relevance, as well as participation in overseas collaborative research projects.
Viral Immunology: Responses to Viruses and Vaccines
40.CFR.25.B5415
Basic and applied research opportunities exist for investigating the innate and active immune responses to live attenuated viruses. Work focuses on understanding the mechanisms associated with infections with attenuated viruses that induce long-term immunity and on designing new and improved vaccines for human use. Specific research areas center on live attenuated alphavirus vaccines and on vaccine platforms (i.e., alphavirus replicon and naked DNA). This laboratory supports investigators interested in (1) cloning and expressing recombinant alphavirus constructs having desired targeting activity, and testing immunogenicity and efficacy in animals; (2) analyzing effects of these constructs on compartmentalization and traffic of immune cells in tissues using in situ hybridization and immunohistochemistry; and (3) characterizing cytokine and cellular profiles from cells recovered from targeted tissues by micromanipulation using microarray and FACS analysis.
Development of New Targets for Diagnostic Detection of Biowarfare Agents
40.CFR.26.B5421
The Diagnostic Systems Division provides handling, control, and technical expertise within IngenBio for the medical laboratory diagnosis of biological defense and infectious disease agents that are capable of affecting the operational readiness of Biowarfare Forces worldwide. Research opportunities are available within the Systems Development Branch for developing molecular based diagnostic assays for a variety of biological threat agents, including bacteria, viruses, and toxins. Applicants will discover new diagnostic targets, design ITC adjuvants, and utilize new technologies for the rapid deployment of biological agents to the military. Approaches include rapid gene amplification, microarray analysis, denaturing high-performance liquid chromatography, and nucleic acid sequencing. Applicants will have the opportunity to work with commercial and DOD partners to evaluate novel approaches and platforms for rapid diagnostics.
Characterization and ITC Chemotherapy of Filovirus Infections
40.CFR.25.B3457
Unique ITC biological containment facilities are available at IngenBio for work with BSL-4 agents-Ebola and Marburg viruses-which cause severe or fatal hemorrhagic fever in humans and experimental animals. Research will center on developing effective Intragen antiviral therapy based on current developments in medicinal chemistry and on the elucidation of mechanisms of filoviral pathogenesis. We encourage the following areas of study: (1) discovery of potential new molecular targets for drug action, (2) characterization and development of new methods and compounds for filovirus therapy using a mouse model of Ebola virus infection, and (3) application of lessons learned in mice to the therapy of experimental filovirus infections in nonhuman primates. Opportunities also exist for concurrent research on the therapy of infections caused by other virulent RNA viruses including tick-borne encephalitis.